Similar Posts
Speculative Option Buying: A Smarter Way to Trade Directional Options
Past performance is not necessarily indicative of future results.Trading or investing whether on margin or otherwise carries a high level of risk, and may not be suitable for all persons. Leverage can work against you as well as for you. Before deciding to trade or invest you should carefully consider your investment objectives, level of…
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) – Bio Tech Winners
June 21, 2024 by Leave a Comment Last Updated on June 21, 2024 by [#item_full_content] Like this: Like Loading… Related Filed Under: biotech news, News Reader Interactions This site uses Akismet to reduce spam. Learn how your comment data is processed. Source link
Affluent investors too feel the pinch as markets turn wobbly from lofty highs
Several affluent individual investors saw their wealth erode by 10-18% in the recent sell-off after witnessing it grow in the September quarter. According to data from primeinfobase.com, the value of the portfolios of Radhakishan Damani, Rakesh Jhunjhunwala‘s family, Ashish Dhawan and Nemish Shah, among others, fell amid the 10% decline in the Nifty since Sept…
Coal price
The Slump in coal prices is going to have some impacts. Firstly, for the coal producers themselves, a price at its lowest in three years after a couple of years of high inflation in their input costs means their bottom line will be hammered. Secondly, a reduction in royalties for the government. Some uneconomic mines…
BofA on Trump Policy
by Calculated Risk on 11/06/2024 02:51:00 PM CR Note: I’ll be assessing the impact of Trump’s election on the economy, but we have to remember he doesn’t do most of what he says. For example, in 2016 he promised to deport 10 million residents, but that never happened. He said he’d repeal and replace the…
ACL – Australian Clinical Labs Limited
Update on Crescent Entities and Crescent Co-Investors’ Shareholding Crescent Capital Partners Management Pty Ltd (“Crescent”) in its capacity as manager of the interests held by the Crescent Entities and Crescent Co-Investors1 (“Crescent Interests”) today announced that it has entered into an underwriting agreement to sell 14.3% of the issued shares outstanding in Australian Clinical Labs…